Use of immune checkpoint inhibitors in patients with lung cancer and multiple sclerosis.

Non-small cell lung cancer (NSCLC) constitutes 80-85% of lung cancer cases and is a leading cause of cancer-related mortality. Most patients are diagnosed at metastatic stages, where curative treatment is rarely an option and the primary goal is to prolong survival while maintaining quality of life. Since NSCLC is often diagnosed in elderly individuals, comorbidities must also be considered in the treatment planning.